It came to the Investment community's attention that Oncothyreon may not have a presentation at ASCO.
CC is Monday May 11 at 330 CST. I suggest you listen.
Marker makers trade amongst themselves to make a market for the stock. If you think sub $4 is cheap, maybe you should buy some more.
Meanwhile we wait for the announcement that the trial is open for enrollment.
Prediction, it will enroll quickly. People with MF have been waiting. Janssen will not have to educate or cajole. The word is out.
droid, I agree. I'm thinking possible fast track of drug in uremic pruritus. I don't think people realize how many dialysis patients there really are. it is common for these pts to receive IV meds on day of dialysis. no special trip!
CUTTING EDGE ADVANCES IN MYELOPROLIFERATIVE NEOPLASMS
Scientific Chairs: Ayalew Tefferi (Mayo Clinic, Minnesota, USA)
Reyhan Diz Küçükkaya (Istanbul Bilim University, Istanbul, Turkey)
Clonal Origination and Evolution in MPN: Radek Skoda (University Hospital Basel, Basel, Switzerland)
Current Prognostication and Treatment of ET, PV and PMF: Ayalew Tefferi (Mayo Clinic, Minnesota, USA)
Contemporary Science and Practice in Mast Cell and Eosinophilic Disorders: Animesh Pardanani (Mayo Clinic Rochester, Minnesota, USA)
Tend to agree. Kirkman is getting old. Big pharma may actually want to play with the three toys he's accumulated: ONT-380, ONT-10, and Protocells.
He's done a good job, but you can't keep going forever. It will take three plus years to see any revenue from these toys. Long ONTY
No, but perhaps it is a bit too kind. I can't help but think how different things would be if the trial design for stimuvax would have been a liitle different. CCRT did OK. Merck had the reigns, not Kirkman.
As for obtaining the full rights to ONT-380 from ARRAY. Good move there?
Have a great memorial day weekend!
The CC highlighted how boring they are and how boring their business is. Yawn.
Could break 6.
That's why there are a lot of us lining up to sell the ASCO bump.
will there be one more bump. If there is, it should be a good one, like 4.50.
What has happeed with ONTY as ASCO is a good example of how rapidly things can change.
And/Or, (FYI, I'm long ONTY, not bashin', just sayin'), certain entities will take a huge short position and sit on the stock for a while. Newbies should exercise caution.
US, sites in 10 states, CA 3, NY 3, IL 1, MD 1, MI 1, MO 1, NC 1, PA 1, TX 1, WA 1,
Belgium 2, France 6, Germany 8, Spain 1, Taiwan 2.
Uremic pruritis is a special kind of "itch" as I understand it. pertaining exclusively to hemodialysis patients. I'm hoping that the top line data is positive for CARA, as it prepares to conduct the PH III studies on their non-addictive pain reliever. I'm trying to trade this stock, but I'm wondering if I shouldn't instead be accumulating it for the possibility of a buyout.
Smart investors buying in anticipation of imminent official announcement of trial commencement.
Predict a small Pop upon announcement, and a Big Pop when trial is fully enrolled, which will come soon after. But the real victory pay off will come next winter.
Congratulations to all the persistent ones. Compared to what we've been through so far, this next leg of the journey seem like the blink of an eye.
Currently high on a similar victory (Novavax), that has shown me how good it can feel.